Literature DB >> 31241981

Temporal induction of intestinal epithelial hypoxia-inducible factor-2α is sufficient to drive colitis.

Sumeet Solanki1, Samantha N Devenport1,2, Sadeesh K Ramakrishnan1, Yatrik M Shah1,3.   

Abstract

Hypoxia is a notable feature of inflammatory bowel disease and chronic induction of hypoxia-inducible factor (HIF)-1α and HIF-2α (endothelial PAS domain protein 1, EPAS1) play important, but opposing, roles in its pathogenesis. While activation of HIF-1α decreases intestinal inflammation and is beneficial in colitis, activation of HIF-2α exacerbates colitis and increases colon carcinogenesis in animal models, primarily due to the role of epithelial HIF-2α in mounting a potent inflammatory response. Previous work from our laboratory showed that mice overexpressing intestinal epithelial HIF-2α led to massive intestinal inflammation and decreased survival. As oxygen homeostasis and HIFs are critical in embryonic development, it is not clear whether the observed intestinal inflammatory response was secondary to developmental defects. To address this question, the present study used a mouse model to temporally modulate expression of intestinal epithelial HIF-2α to assess its role in mediating inflammatory response. Remarkably, activation of HIF-2α in intestinal epithelial cells in adult mice increased expression of proinflammatory mediators; however, no decrease in survival was observed. Furthermore, in an acute model of colitis, activation of HIF-2α was sufficient to exacerbate colitis. These data confirm our previous finding that epithelial HIF-2α mediates inflammatory response and demonstrates that activation of HIF-2α is sufficient to exacerbate colitis.NEW & NOTEWORTHY Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disease of the intestinal tract. Hypoxia and activation of its downstream transcription factors hypoxia-inducible factor (HIF)-1α and HIF-2α are notable features of IBD. HIF-1α has well-characterized protective roles in IBD; however, the role of HIF-2α has been less studied. Using novel HIF-2α mouse models, we show that activation of HIF-2α in intestinal epithelial cells is sufficient to exacerbate colitis.

Entities:  

Keywords:  colitis; hypoxia; hypoxia-inducible factor-2α

Mesh:

Substances:

Year:  2019        PMID: 31241981      PMCID: PMC6734372          DOI: 10.1152/ajpgi.00081.2019

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  45 in total

1.  Selective induction of mucin-3 by hypoxia in intestinal epithelia.

Authors:  Nancy A Louis; Kathryn E Hamilton; Geraldine Canny; Laurie L Shekels; Samuel B Ho; Sean P Colgan
Journal:  J Cell Biochem       Date:  2006-12-15       Impact factor: 4.429

2.  Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice.

Authors:  Matthew Taylor; Aijuan Qu; Erik R Anderson; Tsutomu Matsubara; Angelical Martin; Frank J Gonzalez; Yatrik M Shah
Journal:  Gastroenterology       Date:  2011-03-17       Impact factor: 22.682

3.  Up-regulation of WNT8B mRNA in human gastric cancer.

Authors:  Tetsuroh Saitoh; Tetsuya Mine; Masaru Katoh
Journal:  Int J Oncol       Date:  2002-02       Impact factor: 5.650

4.  Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis.

Authors:  Jörn Karhausen; Glenn T Furuta; John E Tomaszewski; Randall S Johnson; Sean P Colgan; Volker H Haase
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

5.  Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency.

Authors:  Yatrik M Shah; Tsutomu Matsubara; Shinji Ito; Sun-Hee Yim; Frank J Gonzalez
Journal:  Cell Metab       Date:  2009-01-15       Impact factor: 27.287

6.  The UCSC Genome Browser.

Authors:  Donna Karolchik; Angie S Hinrichs; W James Kent
Journal:  Curr Protoc Bioinformatics       Date:  2009-12

7.  The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis.

Authors:  Eoin P Cummins; Fergal Seeballuck; Stephen J Keely; Niamh E Mangan; John J Callanan; Padraic G Fallon; Cormac T Taylor
Journal:  Gastroenterology       Date:  2007-10-10       Impact factor: 22.682

8.  Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition.

Authors:  Andreas Robinson; Simon Keely; Jörn Karhausen; Mark E Gerich; Glenn T Furuta; Sean P Colgan
Journal:  Gastroenterology       Date:  2008-01       Impact factor: 22.682

9.  Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade.

Authors:  Yatrik M Shah; Shinji Ito; Keiichirou Morimura; Chi Chen; Sun-Hee Yim; Volker H Haase; Frank J Gonzalez
Journal:  Gastroenterology       Date:  2008-03-10       Impact factor: 22.682

Review 10.  Biology of hypoxia-inducible factor-2alpha in development and disease.

Authors:  S A Patel; M C Simon
Journal:  Cell Death Differ       Date:  2008-02-15       Impact factor: 15.828

View more
  3 in total

Review 1.  Pathway paradigms revealed from the genetics of inflammatory bowel disease.

Authors:  Daniel B Graham; Ramnik J Xavier
Journal:  Nature       Date:  2020-02-26       Impact factor: 49.962

2.  HIF-2α activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron.

Authors:  Rashi Singhal; Sreedhar R Mitta; Nupur K Das; Samuel A Kerk; Peter Sajjakulnukit; Sumeet Solanki; Anthony Andren; Roshan Kumar; Kenneth P Olive; Ruma Banerjee; Costas A Lyssiotis; Yatrik M Shah
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 14.808

3.  Hepcidin sequesters iron to sustain nucleotide metabolism and mitochondrial function in colorectal cancer epithelial cells.

Authors:  Andrew J Schwartz; Joshua W Goyert; Sumeet Solanki; Samuel A Kerk; Brandon Chen; Cristina Castillo; Peggy P Hsu; Brian T Do; Rashi Singhal; Michael K Dame; Ho-Joon Lee; Jason R Spence; Samira Lakhal-Littleton; Matthew G Vander Heiden; Costas A Lyssiotis; Xiang Xue; Yatrik M Shah
Journal:  Nat Metab       Date:  2021-06-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.